BioSpecifics Technologies Corp. (BSTC) Major Shareholder Sells $480,800.00 in Stock
BioSpecifics Technologies Corp. (NASDAQ:BSTC) major shareholder Of Edwin H. Wegman Estate sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, November 29th. The shares were sold at an average price of $48.08, for a total transaction of $480,800.00. Following the sale, the insider now owns 1,005,128 shares in the company, valued at $48,326,554.24. The sale was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
BioSpecifics Technologies stock opened at $51.91 on Monday. The company has a market cap of $350.52 million, a P/E ratio of 30.54 and a beta of 1.45. BioSpecifics Technologies Corp. has a 1-year low of $38.05 and a 1-year high of $54.50.
BioSpecifics Technologies (NASDAQ:BSTC) last posted its earnings results on Thursday, August 9th. The biopharmaceutical company reported $0.59 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.10. The business had revenue of $7.10 million for the quarter, compared to analyst estimates of $7.10 million. BioSpecifics Technologies had a net margin of 49.78% and a return on equity of 19.59%. analysts forecast that BioSpecifics Technologies Corp. will post 2.09 earnings per share for the current fiscal year.
Institutional investors have recently bought and sold shares of the stock. MetLife Investment Advisors LLC bought a new stake in BioSpecifics Technologies during the 4th quarter worth approximately $132,000. Bank of America Corp DE increased its holdings in BioSpecifics Technologies by 466.7% during the 2nd quarter. Bank of America Corp DE now owns 4,086 shares of the biopharmaceutical company’s stock worth $183,000 after acquiring an additional 3,365 shares during the period. Summit Trail Advisors LLC increased its holdings in BioSpecifics Technologies by 3,339.8% during the 1st quarter. Summit Trail Advisors LLC now owns 233,802 shares of the biopharmaceutical company’s stock worth $234,000 after acquiring an additional 227,005 shares during the period. Citadel Advisors LLC bought a new stake in BioSpecifics Technologies during the 2nd quarter worth approximately $264,000. Finally, GSA Capital Partners LLP increased its holdings in shares of BioSpecifics Technologies by 89.7% in the 2nd quarter. GSA Capital Partners LLP now owns 9,500 shares of the biopharmaceutical company’s stock worth $426,000 after buying an additional 4,491 shares during the last quarter. 58.92% of the stock is currently owned by institutional investors and hedge funds.
BioSpecifics Technologies Company Profile
BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brand names.
Featured Article: What does relative strength index mean?
Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.